SE9501567D0 - A new combination - Google Patents

A new combination

Info

Publication number
SE9501567D0
SE9501567D0 SE9501567A SE9501567A SE9501567D0 SE 9501567 D0 SE9501567 D0 SE 9501567D0 SE 9501567 A SE9501567 A SE 9501567A SE 9501567 A SE9501567 A SE 9501567A SE 9501567 D0 SE9501567 D0 SE 9501567D0
Authority
SE
Sweden
Prior art keywords
composition
component
disorders
new combination
phthalancarbonitrile
Prior art date
Application number
SE9501567A
Other languages
English (en)
Swedish (sv)
Inventor
John Evenden
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9501567A priority Critical patent/SE9501567D0/xx
Publication of SE9501567D0 publication Critical patent/SE9501567D0/xx
Priority to ZA962982A priority patent/ZA962982B/xx
Priority to TW085104481A priority patent/TW458777B/zh
Priority to IL11798896A priority patent/IL117988A0/xx
Priority to KR1019970707592A priority patent/KR100419810B1/ko
Priority to TR97/01254T priority patent/TR199701254T1/xx
Priority to SI9630486T priority patent/SI0822813T1/xx
Priority to HU9801946A priority patent/HUP9801946A3/hu
Priority to JP8532425A priority patent/JPH11504037A/ja
Priority to PT96912370T priority patent/PT822813E/pt
Priority to EE9700245A priority patent/EE03553B1/xx
Priority to CZ973356A priority patent/CZ335697A3/cs
Priority to NZ306602A priority patent/NZ306602A/en
Priority to AT96912370T priority patent/ATE216579T1/de
Priority to BR9608252A priority patent/BR9608252A/pt
Priority to PL96323083A priority patent/PL183997B1/pl
Priority to CA002218181A priority patent/CA2218181A1/en
Priority to PCT/SE1996/000526 priority patent/WO1996033710A1/en
Priority to EP96912370A priority patent/EP0822813B1/en
Priority to DE69620878T priority patent/DE69620878T2/de
Priority to ES96912370T priority patent/ES2175089T3/es
Priority to DK96912370T priority patent/DK0822813T3/da
Priority to AU55202/96A priority patent/AU696356C/en
Priority to US08/640,896 priority patent/US5962514A/en
Priority to SK1429-97A priority patent/SK282060B6/sk
Priority to RU97119427/14A priority patent/RU2183955C2/ru
Priority to CN96194810A priority patent/CN1102386C/zh
Priority to ARP960102323A priority patent/AR002990A1/es
Priority to YU25696A priority patent/YU25696A/sh
Priority to IS4585A priority patent/IS1821B/is
Priority to NO19974921A priority patent/NO317057B1/no
Priority to HK98101990A priority patent/HK1002853A1/xx
Priority to US09/351,071 priority patent/US6184219B1/en
Priority to US09/351,070 priority patent/US6172105B1/en
Priority to US09/351,069 priority patent/US6169098B1/en
Priority to US09/349,590 priority patent/US6184218B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9501567A 1995-04-27 1995-04-27 A new combination SE9501567D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination
ZA962982A ZA962982B (en) 1995-04-27 1996-04-15 A new combination
TW085104481A TW458777B (en) 1995-04-27 1996-04-15 Pharmaceutical compositions for treating affective disorders
IL11798896A IL117988A0 (en) 1995-04-27 1996-04-21 A new combination of an inhibitor and an antagonist
CN96194810A CN1102386C (zh) 1995-04-27 1996-04-23 5－ht摄取抑制剂与选择性5－ht1a拮抗剂的组合物
CA002218181A CA2218181A1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
DE69620878T DE69620878T2 (de) 1995-04-27 1996-04-23 Kombination eines 5-ht uptakeinibitors mit einem selektiven 5-ht 1a antagonisten
SI9630486T SI0822813T1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
HU9801946A HUP9801946A3 (en) 1995-04-27 1996-04-23 A combination al medicament containing a 5-ht uptake inhibitor and a selective 5-ht1a antagonist and process for producing it
JP8532425A JPH11504037A (ja) 1995-04-27 1996-04-23 ５−ｈｔ取り込み阻害薬と選択的５−ｈｔ▲下１ａ▼アンタゴニストとの組み合わせ
PT96912370T PT822813E (pt) 1995-04-27 1996-04-23 Combinacao de um inibidor da absorcao de 5-ht com um antagonista de 5-ht1a selectivo
EE9700245A EE03553B1 (et) 1995-04-27 1996-04-23 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
CZ973356A CZ335697A3 (cs) 1995-04-27 1996-04-23 Směs 5-HT inhibitoru se selektivním 5-HT 1A antagonistem a farmaceutický prostředek, který je obsahuje
NZ306602A NZ306602A (en) 1995-04-27 1996-04-23 A fast onset combination of a 5-ht-reuptake inhibitor and a selective 5-ht1a antagonist in its r-enantiomer form such as 5-carbamoyl-8-fluoro-3,4-dihydro-2h-1-benzopyran derivative
AT96912370T ATE216579T1 (de) 1995-04-27 1996-04-23 Kombination eines 5-ht uptakeinibitors mit einem selektiven 5-ht 1a antagonisten
BR9608252A BR9608252A (pt) 1995-04-27 1996-04-23 Combinação de um primeiro componente que é um inibidor de reabsorção de 5-ht e um segundo componente que é antagonista de 5-th uso da combinação processos para o tratamento de disúrbios efetivos e da depressão para a preparaç o da combinaç o e para melhoria do início de ação terapéutica formulação farmacéutica para o suo no tratamento de distúrbios efetivos e kit
PL96323083A PL183997B1 (pl) 1995-04-27 1996-04-23 Środek farmaceutyczny oraz zastosowanie połączenia inhibitora wychwytu zwrotnego 5-HT i selektywnego antagonisty 5-HT
KR1019970707592A KR100419810B1 (ko) 1995-04-27 1996-04-23 5-ht흡수억제제와선택성5-ht1a길항제의조합물
PCT/SE1996/000526 WO1996033710A1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
EP96912370A EP0822813B1 (en) 1995-04-27 1996-04-23 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
TR97/01254T TR199701254T1 (xx) 1995-04-27 1996-04-23 5-HT al�� inhibit�r�n�n selektif 5-HT1A antagonistiyle kombinasyonu.
ES96912370T ES2175089T3 (es) 1995-04-27 1996-04-23 Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
DK96912370T DK0822813T3 (da) 1995-04-27 1996-04-23 Kombination af en 5-HT-optagelsesinhibitor med en selektiv 5-HT 1A-antagonist
AU55202/96A AU696356C (en) 1995-04-27 1996-04-23 A combination of a 5-HT uptake inhibitor with a selective 5-HT1A antagonist
US08/640,896 US5962514A (en) 1995-04-27 1996-04-23 Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist
SK1429-97A SK282060B6 (sk) 1995-04-27 1996-04-23 Kombinácia inhibítora spätnej absorpcie 5-ht so selektívnou protilátkou 5-ht1a, spôsob jej prípravy, farmaceutická formulácia s jej obsahom, jej použitie a kit s jej obsahom
RU97119427/14A RU2183955C2 (ru) 1995-04-27 1996-04-23 Сочетание ингибитора усвоения 5-нт с селективным 5-нт1a антагонистом
ARP960102323A AR002990A1 (es) 1995-04-27 1996-04-25 Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion.
YU25696A YU25696A (sh) 1995-04-27 1996-04-26 Postupak dobijanja kombinacije (r)-5-karbamoil-8-fluoro-3- n,n-disupstituisan-amino-3,4-dihloro-2h-1-bezopirana i farmaceutske formulacije koje ih sadrže
IS4585A IS1821B (is) 1995-04-27 1997-10-09 Samsetning 5-HT upptöku-hemils og valkvæðs 5-HT 1A -mótlyfs
NO19974921A NO317057B1 (no) 1995-04-27 1997-10-24 Kombinasjon av en 5-HT-opptaksinhibitor med en selektiv 5-HT<N>1A</N> antagonist, formulering og kit inneholdende en slik kombinasjon, fremgangsmate for dens fremstilling, og anvendelse derav.
HK98101990A HK1002853A1 (en) 1995-04-27 1998-03-10 A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist
US09/351,071 US6184219B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/351,070 US6172105B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/351,069 US6169098B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders
US09/349,590 US6184218B1 (en) 1995-04-27 1999-07-09 Composition and methods employing it for the treatment of 5-HT-mediated disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination

Publications (1)

Publication Number Publication Date
SE9501567D0 true SE9501567D0 (sv) 1995-04-27

Family

ID=20398119

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination

Country Status (30)

Country Link
US (5) US5962514A (xx)
EP (1) EP0822813B1 (xx)
JP (1) JPH11504037A (xx)
KR (1) KR100419810B1 (xx)
CN (1) CN1102386C (xx)
AR (1) AR002990A1 (xx)
AT (1) ATE216579T1 (xx)
BR (1) BR9608252A (xx)
CA (1) CA2218181A1 (xx)
CZ (1) CZ335697A3 (xx)
DE (1) DE69620878T2 (xx)
DK (1) DK0822813T3 (xx)
EE (1) EE03553B1 (xx)
ES (1) ES2175089T3 (xx)
HK (1) HK1002853A1 (xx)
HU (1) HUP9801946A3 (xx)
IL (1) IL117988A0 (xx)
IS (1) IS1821B (xx)
NO (1) NO317057B1 (xx)
NZ (1) NZ306602A (xx)
PL (1) PL183997B1 (xx)
PT (1) PT822813E (xx)
RU (1) RU2183955C2 (xx)
SE (1) SE9501567D0 (xx)
SK (1) SK282060B6 (xx)
TR (1) TR199701254T1 (xx)
TW (1) TW458777B (xx)
WO (1) WO1996033710A1 (xx)
YU (1) YU25696A (xx)
ZA (1) ZA962982B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
AU4100699A (en) * 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803155D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803156D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
US6331233B1 (en) 2000-02-02 2001-12-18 Honeywell International Inc. Tantalum sputtering target with fine grains and uniform texture and method of manufacture
EP1757600A2 (en) 2000-10-13 2007-02-28 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
AU2003256430A1 (en) * 2002-08-15 2004-03-03 Wyeth AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US7695601B2 (en) * 2006-05-09 2010-04-13 The United States Of America As Represented By The Secretary Of The Army Electrochemical test apparatus and method for its use
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20160154928A1 (en) * 2013-07-12 2016-06-02 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
CA3049464A1 (en) 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
BR9608252A (pt) 1999-05-04
EP0822813A1 (en) 1998-02-11
ATE216579T1 (de) 2002-05-15
TW458777B (en) 2001-10-11
KR100419810B1 (ko) 2004-04-21
NO974921L (no) 1997-12-18
US6172105B1 (en) 2001-01-09
RU2183955C2 (ru) 2002-06-27
US5962514A (en) 1999-10-05
TR199701254T1 (xx) 1998-02-21
ZA962982B (en) 1996-10-28
SK282060B6 (sk) 2001-10-08
PL183997B1 (pl) 2002-08-30
IS4585A (is) 1997-10-09
SK142997A3 (en) 1998-12-02
US6184219B1 (en) 2001-02-06
HUP9801946A2 (hu) 2000-05-28
DK0822813T3 (da) 2002-07-29
AU5520296A (en) 1996-11-18
PT822813E (pt) 2002-10-31
EP0822813B1 (en) 2002-04-24
DE69620878D1 (de) 2002-05-29
EE9700245A (et) 1998-04-15
AU696356B2 (en) 1998-09-10
PL323083A1 (en) 1998-03-02
CZ335697A3 (cs) 1998-06-17
US6169098B1 (en) 2001-01-02
NO974921D0 (no) 1997-10-24
YU25696A (sh) 1999-06-15
ES2175089T3 (es) 2002-11-16
CA2218181A1 (en) 1996-10-31
EE03553B1 (et) 2001-12-17
CN1187768A (zh) 1998-07-15
NZ306602A (en) 1999-04-29
NO317057B1 (no) 2004-08-02
AR002990A1 (es) 1998-05-27
HK1002853A1 (en) 1998-09-25
HUP9801946A3 (en) 2000-12-28
JPH11504037A (ja) 1999-04-06
DE69620878T2 (de) 2002-11-14
WO1996033710A1 (en) 1996-10-31
IS1821B (is) 2002-08-27
KR19990008068A (ko) 1999-01-25
US6184218B1 (en) 2001-02-06
IL117988A0 (en) 1996-08-04
CN1102386C (zh) 2003-03-05

Similar Documents

Publication Publication Date Title
SE9501567D0 (sv) A new combination
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
MY125414A (en) Aminopropylphosphinic acids
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
RU97119427A (ru) Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
BR9810773A (pt) Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
WO2004096118A3 (en) Composition for improving cognition and memory
SE9803157D0 (sv) A new composition
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
SE9804126D0 (sv) New pharmaceutical composition
MXPA02011554A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos.
SE9702066D0 (sv) A new salt
HUP9601680A2 (hu) Benzizotiazolil-szubsztituált amino-metil-krománok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és a vegyületek alkalmazása
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
SE9803158D0 (sv) A new composition
SE9803156D0 (sv) A new composition
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
SE9803155D0 (sv) A new composition
MY133438A (en) Morpholinobenzamide salts
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine